The 5 analysts offering 12-month price forecasts for CureVac NV have a median target of 20.42, with a high estimate of 52.92 and a low estimate of 17.35. The median estimate represents a +10.66% increase from the last price of 18.45.
The current consensus among 7 polled investment analysts is to Hold stock in CureVac NV. This rating has held steady since May, when it was downgraded from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.57
Reporting Date May 25
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.